JPEN J Parenter Enteral Nutr. 2021 Oct 6. doi: 10.1002/jpen.2272. Online ahead of print.
ABSTRACT
BACKGROUND: The glucagon-like peptide 2 (GLP-2) analogue teduglutide is an effective drug for the treatment of patients suffering from short bowel syndrome with intestinal failure (SBS-IF). This intestinotrophic peptide improves intestinal capacity for fluid and nutrient absorption through induction of mucosal growth and reduction of gastrointestinal motility. Clinical trials demonstrated the efficacy of teduglutide in reducing the need for parenteral support. This study describes an SBS-IF patient population receiving teduglutide therapy in a specialized medical care setting.
METHOD: A retrospective analysis was performed using data of patients suffering from non-malignant SBS-IF. They were treated with teduglutide in a multidisciplinary SBS-IF program at a single university medical center between June 2016 and June 2020.
RESULTS: Thirteen patients were treated with teduglutide and included into the final analysis. Mean small bowel length was 82±31cm with 77% of patients having their colon in continuity. Over a median follow-up period of 107 weeks, all patients (13/13, 100%) responded to the therapy with a clinically significant reduction of parenteral support volume. Mean parenteral support reduction increased with therapy duration and ranged from -82.5% at week 24 (n = 13) to -100% in patients (n = 5) who were treated for 144 weeks. Enteral autonomy was achieved in 12/13 (92%). Teduglutide therapy also improved stool frequency and consistency, changed dietary habits and reduced disease-associated sleep disruptions.
CONCLUSION: Integrating SBS-IF patients treated with teduglutide in a pro-active and tight-meshed patient care program significantly improves the clinical outcome leading to an increased proportion of patients who reach enteral autonomy. This article is protected by copyright. All rights reserved.
PMID:34614239 | DOI:10.1002/jpen.2272
